Theriva Biologics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
46.4%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.20next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Spain VCN-01 Dosing-Feasibility Study Initiation | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly14.4MTarget: Sufficient to fund operations into Q1 2027
VCN-01 Clinical Trial Progress (VIRAGE Phase 2b) QuarterlyTarget: Complete close-out and present final subgroup analyses
SYN-004 (Ribaxamase) Cohort Progress Annually2.0Target: Initiate Cohort 3 (dependent on securing additional funding)
Watch Items
- Initiation of Phase 3 VCN-01 trial in metastatic PDACTrigger: Commencement of Spain dosing-feasibility study in H2 2026Action: Monitor clinical trial registry updates and company press releases for first patient dosed
- Securing development funding or strategic partnerships for VCN-01Trigger: Execution of a co-development or licensing agreementAction: Evaluate terms of partnership, upfront payments, and milestone structures to assess cash runway extension
- Regulatory alignment on Phase 2/3 trial protocol for VCN-01 in retinoblastomaTrigger: FDA and EMA agreement on target population and endpoints in 2026Action: Review regulatory filings for protocol finalization and planned trial initiation timelines
Research as of 20 Jun 2026